Tradestie Institutional Equity Comparison Engine
CGEN vs ACHV โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEN Overall Edge
CGEN Captures Institutional Edge (2โ2 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while ACHV counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CGEN trades at 12.4x Forward P/E with 41.3% operating margin (+102.1% YoY revenue) versus ACHV at 35.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro) against ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEN
CGEN 12.4x vs ACHV 35.3x Fwd P/E
Growth & Margin Winner
CGEN
Op Margin 41.3% vs 0.0% ยท YoY +102.1% vs +0.0%
Momentum & Technical Winner
ACHV
1Y +23.2% vs +43.0% ยท 52W Pos 33% vs 69%
Options & Structure Winner
ACHV
BREAKDOWN (57th %ile IV) vs BREAKOUT (23rd %ile IV)
CGEN
NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap
$193.2M
1M Return
+2.54%
1Y Return
+23.17%
Forward P/E
12.4x
Unified AI Score
47.1 / 100
HOLD
Tech 44.0
Fund 52.0
Flow 54.0
Mom 64.0
ACHV
NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap
$692.8M
1M Return
-8.5%
1Y Return
+43.04%
Forward P/E
35.3x
Unified AI Score
56.6 / 100
HOLD
Tech 66.0
Fund 58.0
Flow 57.0
Mom 58.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CGEN +23.17%
ACHV +43.04%
Spread: +24.3 pp (ACHV Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CGEN TTM Op. Margin: 41.3%
ACHV TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEN vs ACHV. Trailing 12-month operating profitability (CGEN 41.3% vs ACHV 0.0%) and valuation multiples (CGEN 12.4x vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CGEN | ACHV | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $193.2M | $692.8M | Larger Scale | ACHV |
| Trailing P/E Ratio Valuation | 5.2x | 35.3x | Lower Multiple | CGEN |
| Forward P/E Ratio Valuation | 12.4x | 35.3x | Lower Multiple | CGEN |
| Revenue Growth (YoY) Growth | +102.1% | +0.0% | Higher Growth | CGEN |
| Operating Margin (TTM) Profitability | 41.3% | 0.0% | Higher Margin | CGEN |
| Net Profit Margin Profitability | 47.9% | 0.0% | Higher Margin | CGEN |
| Return on Equity (ROE) Capital Efficiency | 57.2% | -845.0% | Higher ROE | CGEN |
| 52-Week Range Position Momentum | 33% ($1โ$3) | 69% ($3โ$9) | Stronger Trend | ACHV |
| Beta / 30D Volatility Risk Regime | 1.44ฮฒ ยท 62% Vol | 1.73ฮฒ ยท 62% Vol | Lower Realized Risk | Tie |
| Unified Institutional Score Composite Signal | 47.1 / 100 (HOLD) | 56.6 / 100 (HOLD) | Higher Composite | ACHV |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CGEN vs ACHV Buy Guide
CGEN
BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
57th %ile
IV Regime
Balanced (25thโ60th %ile)
ACHV
BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CGEN nor ACHV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.